Clinical Trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma

U.S., April 11 -- ClinicalTrials.gov registry received information related to the study (NCT06920901) titled 'A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma' on March 27.

Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of APG777 in adult participants with mild-to-moderate asthma.

The duration of the study will be approximately 52 weeks (364 days) for each participant and will consist of a Screening Period, Treatment Period, and Follow-up Period.

Study Start Date: March 27

Study Type: INTERVENTIONAL

Condition: Asthma

Intervention: DRUG: APG777

APG777 subcutaneo...